To confirm the paucity of binding to CD122+ cells in the tumor, we determined in different compartments (blood, spleen, tumor) the proportion of CD122+ CD8+ T cells and NK cells that bind to fluorescently labeled IL-2c. This evidence concerns the gene CD8A and neoplasm.